Altevax SAS

Altevax is developing and will bring to market a patent-pending vaccine technology that is an effective treatment for cancer and also potentially infectious diseases. The technology, which is a new melanin-based adjuvant that embeds antigens in vaccines, has shown superior efficacy in treating tumours in mice when compared with existing methods. The technology induces one of the most effective immune response in the human body, with specific Cytotoxic T-lymphocytes (CD8+ lymphocytes) against the embedded antigen. This technology can be applied to several types of cancers and can be combined with other technologies under development, such as immune checkpoints inhibitors. As melanin is a naturally present compound in the human body, the Altevax technology is likely to have no or little toxic effect.

We are in the preclinical development phase and will form partnerships with pharmaceutical companies to conduct clinical trials on humans and bring a product to market in the next ten years. The family of vaccines based on Altevax’ technology is addressing a market valued at $62 billion today and growing at a 14% annual growth rate.